Humanigen. The maker of Lenzilumab still hopeful for future . Investors not so much.But Covid is making a comeback…

The company is trying to find a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.They looked promising, but somehow it didn't work out too plan. The share price has fallen close to 99 …

Lenzilumab treatment for rare blood cancers are expanding 2023.

A cutting-edge clinical trial for people with a rare blood cancer is being expanded across Australia and potentially beyond. The study is currently underway at  the Royal Adelaide Hospital and the Austin Hospital in Melbourne. Additional sites to be established in New South Wales, Queensland, Victoria, Tasmania. Associate Professor Dan Thomas, the head of the Blood …

%d bloggers like this: